Flyout Menu
donate
MEMBER login
Facebook-f Twitter Linkedin-in Instagram

Highlights from European Association for the Study of Diabetes (EASD) Annual Meeting 2025

Highlights from European Association for the Study of Diabetes (EASD) Annual Meeting 2025

Highlights from EASD Annual Meeting 2025

Join us as we bring you the latest highlights from the European Association for the Study of Diabetes (EASD) Annual Meeting 2025 in Vienna, Austria, taking place 15-19 September 2025!
Supported by an unrestricted educational grant from Lilly and Novo Nordisk.

Click on the tabs below to watch videos from the EASD Annual Meeting 2025. Explore event introductions, key highlights, and the latest updates on the SURPASS-CVOT and STEP UP trials.

Introduction to EASD 2025

Josephine Forbes

Introduction

Sof Andrikopoulos

Welcome to EASD

Chantal Mathieu

President of EASD | Summary of the EASD 2025, looking ahead to EASD 2026

Highlights from EASD 2025

Jennifer Snaith

Latest developments with GLP therapies - TIRTLE1 trial

Jerry Greenfield

Use of adjuncts in type 1 diabetes - emerging studies, the need for guidelines

Josephine Forbes

Inflammation and its role in predicting type 2 diabetes endotypes for diabetes complications

Mark Cooper

Camillo Golgi Lecture: the link between obesity and the complications of diabetes

Natalie Nanayakkara

DiabetPerio Satellite Symposium: Periodontitis: the underestimated sixth complications of diabetes

Sof Andrikopoulos

SOUL trial: effects of oral semaglutide on cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk

Spiros Fourlanos

Heterogeneity in type 1 diabetes

Jane Speight

New EASD guideline: the assessment and management of diabetes distress

Joel Lasschuit

Diabetic Foot Study Group symposium

Roger Chen

Memory loss, cognition and dementia in diabetes

Roger Chen

Potential utility of the combined use of glucose and ketone values

Elif Ekinci

Post hoc analysis of glucose biomarkers in trials of survodutide in people with type 2 diabetes and obesity

Anthony Russell

EASD highlights: precision medicine, early type 1 diabetes, insulin resistance and adipose tissue, and life after GLP-1

Dianna Magliano

Association between timing and consistency of physical activity and type 2 diabetes

Mervyn Kyi

Managing diabetes in inpatients

Katherine Tonks

Mechanisms of and treatments for insulin resistance, and sarcopenia in the use of GLP-1 agonists and GLP-1/GIP agonists

Timothy Davis

Fremantle Diabetes Study: aortic valve replacement in type 2 diabetes, and lipid biomarkers for incident diabetic retinopathy in type 2 diabetes

Gaurav Puri

STRIDE study: pain-free walking in patients with peripheral arterial disease and type 2 diabetes receiving semaglutide or placebo

Christopher Rayner

A gastroenterologist's perspective of EASD

Karin Jandeleit-Dahm

Basic renal sessions: new targets and pathways in kidney disease and function

Rodney Kwok

Renotrue: a machine learning model to better estimate glomerular filtration rate for people with diabetes

Tony Huynh

EASD highlights and Australia's contribution to diabetes research

Manimegalai Manoharan

Incretin therapy in type 1 diabetes

Wendy Davis

Incident sepsis in people with or without type 2 diabetes: the Fremantle Diabetes Study Phase II

Wendy Davis

Achievement of target CGM metrics in people with type 1 diabetes treated with zimislecel (VX-880) in the FORWARD study

Ronald Ma

Claude Bernard Lecture: Precision diabetes: learning from the rare and applying to the common

Uyen Pham

Pediatric-to-adult transition program and early diabetic kidney disease

Yong-Ho Lee

Dementia, diabetes and ageing

Hung-Yuan Li

CATALYST study: mifepristone in patients with difficult-to-control type 2 diabetes with hypercortisolism

Lee-Ling Lim

Changing terminology: diabetes remission vs diabetes reversible vs diabetes cure

Samuel Chen

Diabetes heterogeneity, precision medicine and distress

JinWei Huang

Pregnancy and hyperglycaemia: Type 1 diabetes, screening and prevention

I Ruei Yu

Type 2 diabetes and weight management

SURPASS-CVOT Trial

Stephen Nicholls

Cardiovascular outcomes in participants on tirzepatide versus dulaglutide in SURPASS-CVOT

David D'Alessio

Glycaemic control and metabolic changes in participants on tirzepatide versus dulaglutide in SURPASS-CVOT

Sophia Zoungas

Evolution of renal status in participants on tirzepatide versus dulaglutide in SURPASS-CVOT

So-Hun Kim

SURPASS-CVOT: cardiovascular benefits of tirzepatide in type 2 diabetes

The ADS gratefully acknowledges the support from Lilly for the SURPASS-CVOT Trial videos.

STEP UP Trial

Sean Wharton

Effect of semaglutide 7.2 mg on anthropometric measures of obesity: the STEP UP trial

Michelle Dalton

Control of eating with semaglutide 7.2 mg in adults with obesity: the STEP UP trial

Ted Wu

Effect of semaglutide on body composition and proximal muscle strength: the STEP UP trial

João Fernandes

Impact of once-weekly semaglutide on cardiovascular events in adults with overweight or obesity in a real-world Danish population

Roy Rasalam

Bimagrumab prevents semaglutide-induced muscle mass loss in diet-induced obese mice

Gillian Scott

STEP UP trial: effect of semaglutide 7.2 mg on anthropometric measures of obesity in the treatment of type 2 diabetes

Richard MacIsaac

The STEP UP studies: an overview and the substudies

The ADS gratefully acknowledges the support from Novo Nordisk for the STEP UP Trial videos.

STEP UP Articles:

Introduction

Josephine Forbes

Introduction

Sof Andrikopoulos

Welcome to EASD

Chantal Mathieu

President of EASD | Summary of the EASD 2025, looking ahead to EASD 2026

SURPASS-CVOT Trial

Stephen Nicholls

The cardiovascular outcomes in participants on tirzepatide versus dulaglutide in the SURPASS-CVOT

David D'Alessio

The glycaemic control and metabolic changes in participants on tirzepatide versus dulaglutide in the SURPASS-CVOT

Sophia Zoungas

The evolution of renal status in participants on tirzepatide versus dulaglutide in the SURPASS-CVOT

The ADS gratefully acknowledges the support from Lilly for the SURPASS-CVOT Trial videos.

STEP UP Trial

Sean Wharton

Effect of semaglutide 7.2 mg on anthropometric measures of obesity: the STEP UP trial

Michelle Dalton

Control of eating with semaglutide 7.2 mg in adults with obesity: the STEP UP trial

Ted Wu

Effect of semaglutide on body composition and proximal muscle strength: the STEP UP trial

João Fernandes

Impact of once-weekly semaglutide on cardiovascular events in adults with overweight or obesity in a real-world Danish population

Roy Rasalam

Bimagrumab prevents semaglutide-induced muscle mass loss in diet-induced obese mice

Gillian Scott

STEP UP - an overview

The ADS gratefully acknowledges the support from Novo Nordisk for the STEP UP Trial videos.

STEP UP Articles:

Lilly Logo
The ADS gratefully acknowledges the support from Lilly for the SURPASS-CVOT Trial videos.
The ADS gratefully acknowledges the support from Novo Nordisk for the STEP UP Trial videos.
Click to view SURPASS-CVOT Trial Highlights
Click to View STEP UP Trial Highlights

Click the buttons to view other highlights from the EASD Annual Meeting 2025.

SURPASS-CVOT Trial Highlights
All EASD 2025 Highlights

Highlights will be available at the end of the conference. Stay tuned!

Day 4

Day 4 highlights will be available soon. Stay tuned!

TBC

Diabetes Management & Treatment (T1D & T2D),
Diabetes Research

Webinar Search

Webinar Categories

Disclaimer: This webpage including the open access webinars is intended for use by healthcare professionals only. The presentations and its content cannot be reproduced, copied or provided to other third parties. Please contact the Australian Diabetes Society via email admin@diabetessociety.com.au for any enquiries.

ADS Professional Education Webinars

Disclaimer Notice

By agreeing to this disclaimer notice; you acknowledge that you are a registered healthcare professional accessing the open access clinical educational webinars hosted by the Australian Diabetes Society. The presentations and its content cannot be reproduced, copied or provided to other third parties. Please contact the Australian Diabetes Society via email admin@diabetessociety.com.au for any enquiries.

I ACCEPT
I DO NOT ACCEPT